Astrana Health, Inc. (NASDAQ:ASTH) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 5.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 471,329 shares of the company's stock after purchasing an additional 23,533 shares during the period. Charles Schwab Investment Management Inc. owned about 0.84% of Astrana Health worth $14,861,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the company. State Street Corp acquired a new stake in Astrana Health during the third quarter valued at approximately $91,966,000. Geode Capital Management LLC acquired a new stake in shares of Astrana Health during the 3rd quarter valued at approximately $58,995,000. FMR LLC bought a new position in Astrana Health during the third quarter worth $48,413,000. Loomis Sayles & Co. L P acquired a new position in Astrana Health in the third quarter worth $30,251,000. Finally, Bellevue Group AG acquired a new position in Astrana Health in the third quarter worth $14,727,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Astrana Health Price Performance

ASTH stock traded up $1.00 during trading on Monday, hitting $31.89. The company had a trading volume of 267,512 shares, compared to its average volume of 255,189. The business has a 50 day moving average of $33.97 and a 200 day moving average of $42.49. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of 24.53, a P/E/G ratio of 1.37 and a beta of 1.30. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health, Inc. has a fifty-two week low of $23.12 and a fifty-two week high of $63.20.

Remove Ads

Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The company had revenue of $665.21 million during the quarter, compared to analyst estimates of $617.24 million. As a group, research analysts predict that Astrana Health, Inc. will post 1.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ASTH shares. Bank of America decreased their target price on Astrana Health from $55.00 to $49.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Stifel Nicolaus dropped their target price on Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. Robert W. Baird reduced their price target on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. Macquarie raised shares of Astrana Health to a "hold" rating in a report on Monday, December 16th. Finally, Truist Financial reduced their target price on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Astrana Health has an average rating of "Moderate Buy" and an average price target of $56.17.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.